Influenza vaccination policy-making processes in France and The Netherlands: Framework and determinants.
Identifieur interne : 000075 ( Main/Curation ); précédent : 000074; suivant : 000076Influenza vaccination policy-making processes in France and The Netherlands: Framework and determinants.
Auteurs : Maria Laura Silva [France] ; Lionel Perrier [France] ; John W. Paget [Pays-Bas] ; Anne Mosnier [France] ; Valérie Buthion [France] ; Jean Marie Cohen [France] ; Hans Martin Sp Th [France]Source :
- Health policy (Amsterdam, Netherlands) [ 1872-6054 ] ; 2016.
Descripteurs français
- KwdFr :
- MESH :
- prévention et contrôle : Grippe humaine.
- usage thérapeutique : Vaccins antigrippaux.
- Entretiens comme sujet, France, Humains, Pays-Bas, Personnel administratif, Politique de santé, Processus politique.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Influenza Vaccines.
- prevention & control : Influenza, Human.
- Administrative Personnel, France, Health Policy, Humans, Interviews as Topic, Netherlands, Policy Making.
Abstract
OBJECTIVES
Target groups for seasonal influenza vaccination are nationally defined based on several factors. However, few studies have explored the policy-making processes at the country-level. We investigated key differences in the policy-making process for the development of vaccination recommendations between France (FR) and The Netherlands (NL). This paper presents preliminary results on the evidence used in the decision-making process and focuses on the interactions between the experts and stakeholders.
METHODS
A documentary analysis identified the stakeholders of this process as governmental authorities, research institutions, associations, and manufacturers. This qualitative study included at least one expert from each stakeholder group. Thirty-three semi-structured interviews were performed in 2013 (16 FR, 17 NL). We used NVivo10® to perform a thematic content analysis on the data.
RESULTS
National Immunization Technical Advisory Groups (NITAGs) were the key stakeholders in the development of recommendations. There was no systematic standard evaluation of evidence during the decision-making process in both countries. Likewise, voting was not systematic, although it did occur more often in FR. A declaration of interests was obligatory in both countries. Experts with no conflicts of interest were rare because many depend on private funding for their research on influenza vaccination.
CONCLUSIONS
The transparency of the NITAGs' procedures for the development of recommendations should be improved. We believe improvements might be achieved by the systematic standard evaluation of evidence, consistent voting, clear declarations of interest, and increased public funding for vaccination research.
DOI: 10.1016/j.healthpol.2016.01.005
PubMed: 26806677
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000075
Links to Exploration step
pubmed:26806677Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influenza vaccination policy-making processes in France and The Netherlands: Framework and determinants.</title><author><name sortKey="Silva, Maria Laura" sort="Silva, Maria Laura" uniqKey="Silva M" first="Maria Laura" last="Silva">Maria Laura Silva</name><affiliation wicri:level="1"><nlm:affiliation>University of Lyon, Lyon, France; University of Bordeaux; Research Center Bordeaux Population HealthU1219 Inserm, Bordeaux, France; University Lumière Lyon 2; CNRS, GATELSEUMR 5824, Ecully, France. Electronic address: maria-laura.silva@univ-lyon2.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University of Lyon, Lyon, France; University of Bordeaux; Research Center Bordeaux Population HealthU1219 Inserm, Bordeaux, France; University Lumière Lyon 2; CNRS, GATELSEUMR 5824, Ecully</wicri:regionArea></affiliation></author><author><name sortKey="Perrier, Lionel" sort="Perrier, Lionel" uniqKey="Perrier L" first="Lionel" last="Perrier">Lionel Perrier</name><affiliation wicri:level="1"><nlm:affiliation>University of Lyon, Lyon, France; University Lumière Lyon 2; CNRS, GATELSEUMR 5824, Ecully, France; Direction of Clinical Research and Innovation, DRCI, Léon Bérard Cancer Centre, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University of Lyon, Lyon, France; University Lumière Lyon 2; CNRS, GATELSEUMR 5824, Ecully, France; Direction of Clinical Research and Innovation, DRCI, Léon Bérard Cancer Centre, Lyon</wicri:regionArea></affiliation></author><author><name sortKey="Paget, John W" sort="Paget, John W" uniqKey="Paget J" first="John W" last="Paget">John W. Paget</name><affiliation wicri:level="1"><nlm:affiliation>Netherlands Institute For Health Services Research (NIVEL), Utrecht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Netherlands Institute For Health Services Research (NIVEL), Utrecht</wicri:regionArea></affiliation></author><author><name sortKey="Mosnier, Anne" sort="Mosnier, Anne" uniqKey="Mosnier A" first="Anne" last="Mosnier">Anne Mosnier</name><affiliation wicri:level="1"><nlm:affiliation>Open Rome, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Open Rome, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Buthion, Valerie" sort="Buthion, Valerie" uniqKey="Buthion V" first="Valérie" last="Buthion">Valérie Buthion</name><affiliation wicri:level="1"><nlm:affiliation>University of Lyon, Lyon, France; University Lumière Lyon 2 COACTIS, EA 4161, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University of Lyon, Lyon, France; University Lumière Lyon 2 COACTIS, EA 4161, Lyon</wicri:regionArea></affiliation></author><author><name sortKey="Cohen, Jean Marie" sort="Cohen, Jean Marie" uniqKey="Cohen J" first="Jean Marie" last="Cohen">Jean Marie Cohen</name><affiliation wicri:level="1"><nlm:affiliation>Open Rome, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Open Rome, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Sp Th, Hans Martin" sort="Sp Th, Hans Martin" uniqKey="Sp Th H" first="Hans Martin" last="Sp Th">Hans Martin Sp Th</name><affiliation wicri:level="1"><nlm:affiliation>University of Lyon, Lyon, France; University Claude Bernard Lyon 1, EAM 4128, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University of Lyon, Lyon, France; University Claude Bernard Lyon 1, EAM 4128, Lyon</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26806677</idno><idno type="pmid">26806677</idno><idno type="doi">10.1016/j.healthpol.2016.01.005</idno><idno type="wicri:Area/Main/Corpus">000075</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000075</idno><idno type="wicri:Area/Main/Curation">000075</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000075</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Influenza vaccination policy-making processes in France and The Netherlands: Framework and determinants.</title><author><name sortKey="Silva, Maria Laura" sort="Silva, Maria Laura" uniqKey="Silva M" first="Maria Laura" last="Silva">Maria Laura Silva</name><affiliation wicri:level="1"><nlm:affiliation>University of Lyon, Lyon, France; University of Bordeaux; Research Center Bordeaux Population HealthU1219 Inserm, Bordeaux, France; University Lumière Lyon 2; CNRS, GATELSEUMR 5824, Ecully, France. Electronic address: maria-laura.silva@univ-lyon2.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University of Lyon, Lyon, France; University of Bordeaux; Research Center Bordeaux Population HealthU1219 Inserm, Bordeaux, France; University Lumière Lyon 2; CNRS, GATELSEUMR 5824, Ecully</wicri:regionArea></affiliation></author><author><name sortKey="Perrier, Lionel" sort="Perrier, Lionel" uniqKey="Perrier L" first="Lionel" last="Perrier">Lionel Perrier</name><affiliation wicri:level="1"><nlm:affiliation>University of Lyon, Lyon, France; University Lumière Lyon 2; CNRS, GATELSEUMR 5824, Ecully, France; Direction of Clinical Research and Innovation, DRCI, Léon Bérard Cancer Centre, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University of Lyon, Lyon, France; University Lumière Lyon 2; CNRS, GATELSEUMR 5824, Ecully, France; Direction of Clinical Research and Innovation, DRCI, Léon Bérard Cancer Centre, Lyon</wicri:regionArea></affiliation></author><author><name sortKey="Paget, John W" sort="Paget, John W" uniqKey="Paget J" first="John W" last="Paget">John W. Paget</name><affiliation wicri:level="1"><nlm:affiliation>Netherlands Institute For Health Services Research (NIVEL), Utrecht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Netherlands Institute For Health Services Research (NIVEL), Utrecht</wicri:regionArea></affiliation></author><author><name sortKey="Mosnier, Anne" sort="Mosnier, Anne" uniqKey="Mosnier A" first="Anne" last="Mosnier">Anne Mosnier</name><affiliation wicri:level="1"><nlm:affiliation>Open Rome, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Open Rome, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Buthion, Valerie" sort="Buthion, Valerie" uniqKey="Buthion V" first="Valérie" last="Buthion">Valérie Buthion</name><affiliation wicri:level="1"><nlm:affiliation>University of Lyon, Lyon, France; University Lumière Lyon 2 COACTIS, EA 4161, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University of Lyon, Lyon, France; University Lumière Lyon 2 COACTIS, EA 4161, Lyon</wicri:regionArea></affiliation></author><author><name sortKey="Cohen, Jean Marie" sort="Cohen, Jean Marie" uniqKey="Cohen J" first="Jean Marie" last="Cohen">Jean Marie Cohen</name><affiliation wicri:level="1"><nlm:affiliation>Open Rome, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Open Rome, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Sp Th, Hans Martin" sort="Sp Th, Hans Martin" uniqKey="Sp Th H" first="Hans Martin" last="Sp Th">Hans Martin Sp Th</name><affiliation wicri:level="1"><nlm:affiliation>University of Lyon, Lyon, France; University Claude Bernard Lyon 1, EAM 4128, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University of Lyon, Lyon, France; University Claude Bernard Lyon 1, EAM 4128, Lyon</wicri:regionArea></affiliation></author></analytic><series><title level="j">Health policy (Amsterdam, Netherlands)</title><idno type="eISSN">1872-6054</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administrative Personnel (MeSH)</term><term>France (MeSH)</term><term>Health Policy (MeSH)</term><term>Humans (MeSH)</term><term>Influenza Vaccines (therapeutic use)</term><term>Influenza, Human (prevention & control)</term><term>Interviews as Topic (MeSH)</term><term>Netherlands (MeSH)</term><term>Policy Making (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Entretiens comme sujet (MeSH)</term><term>France (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Humains (MeSH)</term><term>Pays-Bas (MeSH)</term><term>Personnel administratif (MeSH)</term><term>Politique de santé (MeSH)</term><term>Processus politique (MeSH)</term><term>Vaccins antigrippaux (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administrative Personnel</term><term>France</term><term>Health Policy</term><term>Humans</term><term>Interviews as Topic</term><term>Netherlands</term><term>Policy Making</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Entretiens comme sujet</term><term>France</term><term>Humains</term><term>Pays-Bas</term><term>Personnel administratif</term><term>Politique de santé</term><term>Processus politique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>Target groups for seasonal influenza vaccination are nationally defined based on several factors. However, few studies have explored the policy-making processes at the country-level. We investigated key differences in the policy-making process for the development of vaccination recommendations between France (FR) and The Netherlands (NL). This paper presents preliminary results on the evidence used in the decision-making process and focuses on the interactions between the experts and stakeholders.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>A documentary analysis identified the stakeholders of this process as governmental authorities, research institutions, associations, and manufacturers. This qualitative study included at least one expert from each stakeholder group. Thirty-three semi-structured interviews were performed in 2013 (16 FR, 17 NL). We used NVivo10® to perform a thematic content analysis on the data.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>National Immunization Technical Advisory Groups (NITAGs) were the key stakeholders in the development of recommendations. There was no systematic standard evaluation of evidence during the decision-making process in both countries. Likewise, voting was not systematic, although it did occur more often in FR. A declaration of interests was obligatory in both countries. Experts with no conflicts of interest were rare because many depend on private funding for their research on influenza vaccination.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>The transparency of the NITAGs' procedures for the development of recommendations should be improved. We believe improvements might be achieved by the systematic standard evaluation of evidence, consistent voting, clear declarations of interest, and increased public funding for vaccination research.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26806677</PMID><DateCompleted><Year>2017</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2017</Year><Month>03</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-6054</ISSN><JournalIssue CitedMedium="Internet"><Volume>120</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Health policy (Amsterdam, Netherlands)</Title><ISOAbbreviation>Health Policy</ISOAbbreviation></Journal><ArticleTitle>Influenza vaccination policy-making processes in France and The Netherlands: Framework and determinants.</ArticleTitle><Pagination><MedlinePgn>293-305</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.healthpol.2016.01.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0168-8510(16)00006-3</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Target groups for seasonal influenza vaccination are nationally defined based on several factors. However, few studies have explored the policy-making processes at the country-level. We investigated key differences in the policy-making process for the development of vaccination recommendations between France (FR) and The Netherlands (NL). This paper presents preliminary results on the evidence used in the decision-making process and focuses on the interactions between the experts and stakeholders.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A documentary analysis identified the stakeholders of this process as governmental authorities, research institutions, associations, and manufacturers. This qualitative study included at least one expert from each stakeholder group. Thirty-three semi-structured interviews were performed in 2013 (16 FR, 17 NL). We used NVivo10® to perform a thematic content analysis on the data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">National Immunization Technical Advisory Groups (NITAGs) were the key stakeholders in the development of recommendations. There was no systematic standard evaluation of evidence during the decision-making process in both countries. Likewise, voting was not systematic, although it did occur more often in FR. A declaration of interests was obligatory in both countries. Experts with no conflicts of interest were rare because many depend on private funding for their research on influenza vaccination.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The transparency of the NITAGs' procedures for the development of recommendations should be improved. We believe improvements might be achieved by the systematic standard evaluation of evidence, consistent voting, clear declarations of interest, and increased public funding for vaccination research.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Maria Laura</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>University of Lyon, Lyon, France; University of Bordeaux; Research Center Bordeaux Population HealthU1219 Inserm, Bordeaux, France; University Lumière Lyon 2; CNRS, GATELSEUMR 5824, Ecully, France. Electronic address: maria-laura.silva@univ-lyon2.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrier</LastName><ForeName>Lionel</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Lyon, Lyon, France; University Lumière Lyon 2; CNRS, GATELSEUMR 5824, Ecully, France; Direction of Clinical Research and Innovation, DRCI, Léon Bérard Cancer Centre, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paget</LastName><ForeName>John W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Netherlands Institute For Health Services Research (NIVEL), Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosnier</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Open Rome, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buthion</LastName><ForeName>Valérie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>University of Lyon, Lyon, France; University Lumière Lyon 2 COACTIS, EA 4161, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Jean Marie</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Open Rome, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Späth</LastName><ForeName>Hans Martin</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>University of Lyon, Lyon, France; University Claude Bernard Lyon 1, EAM 4128, Lyon, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Health Policy</MedlineTA><NlmUniqueID>8409431</NlmUniqueID><ISSNLinking>0168-8510</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>H</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000288" MajorTopicYN="N">Administrative Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006291" MajorTopicYN="N">Health Policy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007407" MajorTopicYN="N">Interviews as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N">Netherlands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011050" MajorTopicYN="Y">Policy Making</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Health policy</Keyword><Keyword MajorTopicYN="N">Human influenza</Keyword><Keyword MajorTopicYN="N">Interviews</Keyword><Keyword MajorTopicYN="N">NITAG</Keyword><Keyword MajorTopicYN="N">Policy-making</Keyword><Keyword MajorTopicYN="N">Qualitative research</Keyword><Keyword MajorTopicYN="N">Vaccination recommendations</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>05</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>08</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>01</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26806677</ArticleId><ArticleId IdType="pii">S0168-8510(16)00006-3</ArticleId><ArticleId IdType="doi">10.1016/j.healthpol.2016.01.005</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippePaysBasV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000075 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000075 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippePaysBasV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:26806677
|texte= Influenza vaccination policy-making processes in France and The Netherlands: Framework and determinants.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:26806677" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a GrippePaysBasV1
| This area was generated with Dilib version V0.6.35. |  |